ARTL
Artelo Biosciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-86/100
Last price
3.50
▼ 0.01 (0.28%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.50
Prev close
3.51
Day high
3.74
Day low
3.41
Volume
74.56K
Market cap
$1.90M
P/E (TTM)
—
52W range
3.41 – 179.19
Day trading desk
Gap from prior close
-0.28%
Prior close 3.51
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
3.50 – 3.50
Position in range
—
—
ATR (14D)
1.32
37.82% of price
Prior day high
3.75
PDH
Prior day low
3.50
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 486.66K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-14.99%
-16.9%
1M
-42.72%
-43.9%
3M
-61.40%
-65.9%
6M
-94.73%
-112.9%
YTD
-89.50%
-103.7%
1Y
-97.27%
-113.7%
3Y
-98.54%
-180.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARTL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
541
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 28, 25 | MATSUI CONNIE L Director |
CONVERSION | 38.35K | $136.13K | Direct |
| Oct 28, 25 | FAVORITO TAMARA A. Director |
CONVERSION | 6.85K | $24.30K | Direct |
| Oct 28, 25 | GORGAS GREGORY D Chief Executive Officer |
CONVERSION | 9.59K | $34.03K | Direct |
| Oct 28, 25 | FAVORITO TAMARA A. Director |
CONVERSION | 6.85K | $24.30K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FAVORITO TAMARA A. |
Director | 0 | Conversion of Exercise of derivative security |
GORGAS GREGORY D |
Chief Executive Officer | 0 | Conversion of Exercise of derivative security |
MATSUI CONNIE L |
Director | 0 | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.90M
Enterprise value$-2.38M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-12.67M
EPS (TTM)$-132.38
Free cash flow$-8.57M
Total cash$4.20M
Total debt$49.00K
Book value / share$10.74
Shares outstanding547.77K
Float510.24K
Short % of float4.12%
Dividend yield0.00%
Beta (5Y)-0.07
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.93
PEG ratio—
Price / sales—
Price / book0.32
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-705.71%
Return on assets-127.92%
Debt / equity0.98
Current ratio3.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $5.42M | $5.99M | $5.70M | $4.32M | -9.5% |
| Selling, general & admin | $5.98M | $4.12M | $4.23M | $5.96M | +45.3% |
| Total operating expense | $11.40M | $10.11M | $9.93M | $10.29M | +12.8% |
| Operating income | -$11.40M | -$10.11M | -$9.93M | -$10.29M | -12.8% |
| Net interest income | -$277.00K | $0 | $0 | -$3.00K | — |
| Pre-tax income | -$12.88M | -$9.83M | -$9.29M | -$10.08M | -31.1% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$12.88M | -$9.83M | -$9.29M | -$10.08M | -31.1% |
| Net income to common | -$12.88M | -$9.83M | -$9.29M | -$10.08M | -31.1% |
| Basic EPS | -37.56 | -54.90 | -56.52 | -64.08 | +31.6% |
| Diluted EPS | -37.56 | -54.90 | -56.52 | -64.08 | +31.6% |
| EBIT | -$12.60M | -$9.83M | -$9.93M | -$10.08M | -28.3% |
| EBITDA | -$12.60M | -$9.83M | -$9.93M | -$10.08M | -28.3% |
| Basic shares | 343.00K | 179.00K | 164.44K | 157.39K | +91.6% |
| Diluted shares | 343.00K | 179.00K | 164.44K | 157.39K | +91.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $600.00K | $2.34M | $2.81M | $6.89M | -74.3% |
| Cash & short-term investments | $600.00K | $2.34M | $10.43M | $17.53M | -74.3% |
| Total current assets | $695.00K | $2.56M | $10.98M | $18.32M | -72.8% |
| Property, plant & equipment | $64.00K | $99.00K | $21.00K | $60.00K | -35.4% |
| Goodwill & intangibles | $2.04M | $2.04M | $2.04M | $2.04M | 0.0% |
| Total assets | $2.80M | $4.70M | $13.04M | $20.42M | -40.4% |
| Total current liabilities | $4.04M | $1.77M | $1.29M | $998.00K | +128.2% |
| Current debt | $609.00K | — | — | — | — |
| Total debt | $678.00K | $104.00K | $23.00K | $63.00K | +551.9% |
| Total liabilities | $4.07M | $1.84M | $1.29M | $1.02M | +121.2% |
| Retained earnings | -$63.02M | -$50.14M | -$40.31M | -$31.02M | -25.7% |
| Shareholder equity | -$1.27M | $2.86M | $11.75M | $19.40M | -144.5% |
| Working capital | -$3.35M | $785.00K | $9.69M | $17.32M | -526.6% |
| Net tangible assets | -$3.31M | $818.00K | $9.71M | $17.36M | -504.8% |
| Shares issued | 673.01K | 189.19K | 177.16K | 158.65K | +255.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$12.88M | -$9.83M | -$9.29M | -$10.08M | -31.1% |
| Stock-based compensation | $1.14M | $818.00K | $1.02M | $2.46M | +39.6% |
| Change in working capital | $1.79M | $937.00K | $703.00K | -$172.00K | +90.9% |
| Operating cash flow | -$8.52M | -$8.35M | -$8.21M | -$8.01M | -2.0% |
| Investing cash flow | -$62.00K | $7.77M | $3.51M | $2.96M | -100.8% |
| Financing cash flow | $6.87M | $112.00K | $567.00K | $0 | +6,031.3% |
| Free cash flow | -$8.52M | -$8.35M | -$8.21M | -$8.01M | -2.0% |
| End cash position | $600.00K | $2.34M | $2.81M | $6.89M | -74.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $876.00K | $773.00K | $893.00K | $1.27M | $1.87M | — | +13.3% |
| Selling, general & admin | $1.63M | $1.92M | $1.89M | $1.81M | $1.28M | — | -15.0% |
| Total operating expense | $2.50M | $2.69M | $2.79M | $3.09M | $3.15M | — | -6.8% |
| Operating income | -$2.50M | -$2.69M | -$2.79M | -$3.09M | -$3.15M | — | +6.8% |
| Net interest income | $36.00K | -$123.00K | -$107.00K | -$106.00K | -$71.00K | — | +129.3% |
| Pre-tax income | -$2.43M | -$2.96M | -$4.17M | -$3.12M | -$3.22M | — | +18.0% |
| Tax provision | $0 | — | $0 | $0 | $0 | $0 | — |
| Net income | -$2.43M | -$2.96M | -$4.17M | -$3.12M | -$3.22M | — | +18.0% |
| Net income to common | -$2.43M | -$2.96M | -$4.17M | -$3.12M | -$3.22M | — | +18.0% |
| Basic EPS | -0.89 | -4.00 | — | -11.91 | -16.86 | -12.55 | +77.8% |
| Diluted EPS | -0.89 | -4.00 | — | -11.91 | -16.86 | -12.55 | +77.8% |
| EBIT | -$2.42M | -$2.83M | -$4.07M | -$3.01M | -$3.15M | — | +14.6% |
| EBITDA | -$2.42M | -$2.83M | -$4.07M | -$3.01M | -$3.15M | — | +14.6% |
| Basic shares | 2.73M | 739.00K | — | 262.33K | 191.04K | 189.00K | +269.0% |
| Diluted shares | 2.73M | 739.00K | — | 262.33K | 191.04K | 189.00K | +269.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.20M | $10.27M | $600.00K | $1.72M | $2.07M | -59.1% |
| Cash & short-term investments | $4.20M | $10.27M | $600.00K | $1.72M | $2.07M | -59.1% |
| Total current assets | $4.37M | $10.42M | $695.00K | $1.83M | $2.23M | -58.1% |
| Property, plant & equipment | $46.00K | $55.00K | $64.00K | $73.00K | $82.00K | -16.4% |
| Goodwill & intangibles | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | 0.0% |
| Total assets | $6.46M | $12.52M | $2.80M | $4.27M | $4.36M | -48.4% |
| Total current liabilities | $1.46M | $5.83M | $4.04M | $4.86M | $5.71M | -75.0% |
| Current debt | — | $660.00K | $609.00K | $875.00K | $791.00K | — |
| Total debt | $49.00K | $719.00K | $678.00K | $954.00K | $878.00K | -93.2% |
| Total liabilities | $1.46M | $5.85M | $4.07M | $4.90M | $5.76M | -75.0% |
| Retained earnings | -$68.40M | -$65.97M | -$63.02M | -$58.85M | -$55.73M | -3.7% |
| Shareholder equity | $5.00M | $6.67M | -$1.27M | -$633.00K | -$1.41M | -25.1% |
| Working capital | $2.92M | $4.59M | -$3.35M | -$3.03M | -$3.48M | -36.5% |
| Net tangible assets | $2.96M | $4.63M | -$3.31M | -$2.67M | -$3.44M | -36.2% |
| Shares issued | 3.49M | 876.03K | 673.01K | 518.50K | 234.81K | +297.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$2.43M | -$2.96M | -$4.17M | -$3.12M | -$3.22M | — | +18.0% |
| Stock-based compensation | $570.00K | $401.00K | $368.00K | $432.00K | $150.00K | — | +42.1% |
| Change in working capital | -$3.15M | $1.13M | -$479.00K | -$818.00K | $2.50M | — | -378.2% |
| Operating cash flow | -$5.03M | -$1.19M | -$2.91M | -$3.50M | -$514.00K | — | -322.6% |
| Investing cash flow | — | — | $188.00K | -$250.00K | $0 | $0 | — |
| Financing cash flow | -$1.06M | $10.86M | $1.61M | $3.44M | $1.82M | — | -109.8% |
| Free cash flow | -$5.03M | -$1.19M | -$2.91M | -$3.50M | -$514.00K | — | -322.6% |
| End cash position | $4.20M | $10.27M | $600.00K | $1.72M | $2.07M | — | -59.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | -42.39 | -1.08 | +97.4% |
| Sep 2025 | — | -107.19 | — |
| Jun 2025 | -113.13 | -151.47 | -33.9% |
| Mar 2025 | -21.06 | -116.64 | -453.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.11%
Held by institutions2.38%
Institutions holding7
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.39
-20.29% from price
SMA 20
4.55
-24.01% from price
SMA 50
5.74
-39.73% from price
SMA 100
8.57
-59.18% from price
SMA 200
25.06
-86.19% from price
EMA 12
4.16
-15.85% from price
EMA 26
4.85
-27.83% from price
EMA 50
6.42
-45.48% from price
RSI (14)
37.3
Neutral
MACD (12,26,9)
-0.69
Hist -0.05
ATR (14)
1.32
38.26% of price
Realised vol 30D
230.9%
Annualised
Bollinger upper
6.48
20, 2σ
Bollinger lower
2.63
20, 2σ
50 / 200 cross
Death
5.74 vs 25.06
Trend bias
Below 200
-86.19%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-1.71
Less volatile than market
Correlation to SPY
-0.08
Largely independent
Realised vol 30D
230.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-97.4%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
1.32
38.26% of price
Beta (reported)
-0.07
5Y monthly, from filing
Short interest
Shares short
22.55K
Prior 9.48K
Change vs prior
+137.9%
Shorts adding
% of float
4.12%
Normal
% of shares out
4.12%
Against total outstanding
Days to cover
0.2
Liquid
Float
510.24K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 25 | Maxim Group | DOWNGRADE | Buy | Hold |
| Sep 8, 25 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Aug 26, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 18, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 6, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 4, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 8, 25 | D. Boral Capital | UPGRADE | Hold | Buy |
| Jun 11, 25 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Jun 6, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 28, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 2, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 4, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJun 21, 2019
Last split1:9
Split dateAug 31, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-27
Periodic Financial Reports
10-Q/A · 2026-08-20
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-17
Proxy Statements
DEFA14A · 2026-07-16
Proxy Statements
DEFA14A · 2026-07-02
Proxy Statements
PRER14A · 2026-06-22
Proxy Statements
DEFA14A · 2026-06-05
Headlines
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
GlobeNewswire · 14d ago
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
GlobeNewswire · 21d ago
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 29d ago
Artelo Biosciences Announces Reverse Stock Split
GlobeNewswire · 41d ago
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
GlobeNewswire · 48d ago
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
GlobeNewswire · 51d ago
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
GlobeNewswire · 55d ago
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
GlobeNewswire · 77d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.